These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Production of Secreted Carbohydrates that Present Immunologic Similarities with the Cryptococcus Glucuronoxylomannan by Members of the Trichosporonaceae Family: A Comparative Study Among Species of Clinical Interest. de Andrade IB; Almeida MA; Figueiredo-Carvalho MHG; Coelho RA; Chaves ALDS; Frases S; Zancopé-Oliveira RM; Brito-Santos F; Almeida-Paes R Mycopathologia; 2021 Jun; 186(3):377-385. PubMed ID: 33956292 [TBL] [Abstract][Full Text] [Related]
5. Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties. Ramos CL; Fonseca FL; Rodrigues J; Guimarães AJ; Cinelli LP; Miranda K; Nimrichter L; Casadevall A; Travassos LR; Rodrigues ML Eukaryot Cell; 2012 Sep; 11(9):1086-94. PubMed ID: 22562469 [TBL] [Abstract][Full Text] [Related]
6. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan. Albuquerque PC; Cordero RJ; Fonseca FL; Peres da Silva R; Ramos CL; Miranda KR; Casadevall A; Puccia R; Nosanchuk JD; Nimrichter L; Guimaraes AJ; Rodrigues ML Fungal Genet Biol; 2012 Nov; 49(11):943-54. PubMed ID: 23010152 [TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter. Fonseca FL; Nohara LL; Cordero RJ; Frases S; Casadevall A; Almeida IC; Nimrichter L; Rodrigues ML Infect Immun; 2010 Sep; 78(9):3861-70. PubMed ID: 20547742 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans. Brandt S; Thorkildson P; Kozel TR Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925 [TBL] [Abstract][Full Text] [Related]
9. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160 [TBL] [Abstract][Full Text] [Related]
10. Increased release of glucuronoxylomannan antigen and induced phenotypic changes in Trichosporon asahii by repeated passage in mice. Karashima R; Yamakami Y; Yamagata E; Tokimatsu I; Hiramatsu K; Nasu M J Med Microbiol; 2002 May; 51(5):423-432. PubMed ID: 11990495 [TBL] [Abstract][Full Text] [Related]
11. Isolation and purification of antigenic components of Cryptococcus. Wozniak KL; Levitz SM Methods Mol Biol; 2009; 470():71-83. PubMed ID: 19089377 [TBL] [Abstract][Full Text] [Related]
12. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy. da Silva TA; Hauser PJ; Bandey I; Laskowski T; Wang Q; Najjar AM; Kumaresan PR Cytotherapy; 2021 Feb; 23(2):119-130. PubMed ID: 33303326 [TBL] [Abstract][Full Text] [Related]
13. Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct. Albuquerque PC; Fonseca FL; Dutra FF; Bozza MT; Frases S; Casadevall A; Rodrigues ML Future Microbiol; 2014; 9(2):147-61. PubMed ID: 24571070 [TBL] [Abstract][Full Text] [Related]
14. Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. McFadden DC; Fries BC; Wang F; Casadevall A Eukaryot Cell; 2007 Aug; 6(8):1464-73. PubMed ID: 17601878 [TBL] [Abstract][Full Text] [Related]
15. Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans. Grijpstra J; Gerwig GJ; Wösten H; Kamerling JP; de Cock H Eukaryot Cell; 2009 Aug; 8(8):1165-73. PubMed ID: 19542308 [TBL] [Abstract][Full Text] [Related]
16. The still obscure attributes of cryptococcal glucuronoxylomannan. Rodrigues ML; Fonseca FL; Frases S; Casadevall A; Nimrichter L Med Mycol; 2009 Dec; 47(8):783-8. PubMed ID: 19343609 [TBL] [Abstract][Full Text] [Related]
17. The Overlooked Glycan Components of the Cryptococcus Capsule. Fonseca FL; Reis FCG; Sena BAG; Jozefowicz LJ; Kmetzsch L; Rodrigues ML Curr Top Microbiol Immunol; 2019; 422():31-43. PubMed ID: 30203395 [TBL] [Abstract][Full Text] [Related]
18. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils. Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070 [TBL] [Abstract][Full Text] [Related]